Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

Abstract: Benzo-heterocyclic compounds of the formula: ##STR1## wherein R.sup.1 is a lower alkyl group; R.sup.2 is a halogen atom or a group of the formula ##STR2## (wherein R.sup.4 and R.sup.5 combine together with the nitrogen atom to which they bind to form a 5- or 6-membered saturated heterocyclic group which may optionally contain an oxygen atom or nitrogen atom within the ring as an additional hetero atom and may also optionally have a substituent selected from a lower alkyl or hydroxy group on the hetero ring); R.sup.3 is an amino or nitro group; X is a halogen atom; and n is an integer of 1 or 2, and a salt thereof, which have excellent antimicrobial activities and are useful as an antimicrobial agent, or as an intermediate for the preparation of an active compound.